REGENXBIO Reports Fourth Quarter and Full-Year 2019 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/28/2026
- Wall St futures drop as oil spikes after Trump rejects Iran peace proposal
- S&P 500 breadth hits lowest level since dot-com bubble, Goldman says
- Nvidia’s AI dominance funds historic $150 billion buyback
- Oil gains over 3% as US-Iran peace talks in stalemate
- Stock action shows confidence in central banks: BofA’s Hartnett
- White House blocks CNN from Air Force One trip, Washington Post reports
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Exclusive-SK Hynix's Solidigm weighs IPO that could value the unit at up to $150 billion, sources say
- Wall Street ends higher as investors buy AI stocks; Microsoft rallies
- Fox Factory sells Marucci Sports for $225M, cuts debt
Regenxbio (RGNX) Misses Q4 EPS by 28c, Revenues Miss
February 26, 2020 4:44 PM ESTRegenxbio (NASDAQ: RGNX) reported Q4 EPS of ($0.72), $0.28 worse than the analyst estimate of ($0.44). Revenue for the quarter came in at $11.77 million versus the consensus estimate of $39.67 million.
Additional data from RGX-314 Phase I/IIa trial for wet AMD expected in 1H 2020RGX-314 clinical trials for treatment of wet AMD and diabetic retinopathy expected to advance in 2020 using subretinal and suprachoroidal delivery... More